A review of studies on the pathogenesis and preclinical drug therapy of acute respiratory distress syndrome
10.3760/cma.j.cn121430-20200107-00111
- VernacularTitle:急性呼吸窘迫综合征的发病机制及临床前药物研究
- Author:
Leilei ZHOU
1
;
Xianming ZHANG
Author Information
1. 贵州医科大学，贵阳 550004
- From:
Chinese Critical Care Medicine
2020;32(3):378-381
- CountryChina
- Language:Chinese
-
Abstract:
Acute respiratory distress syndrome (ARDS) is a serious disease with high mortality, which is characterized by non-cardiogenic pulmonary edema and hypoxemia. In recent years, the development of supportive therapy has reduced the mortality to some extent, however, the high cost of treatment, side effects and the high mortality of moderate and severe ARDS limit its efficacy. So it is necessary to strengthen the research on specific drugs. The core pathological changes of ARDS are the uncontrolled inflammatory response and the impairment of pulmonary vascular endothelium and alveolar epithelial barrier function. Therefore, regulating the intensity of inflammatory response and promoting the endothelial and epithelial barrier have become two key factors in the current drug treatment of ARDS. This article summarizes the pathogenesis of ARDS and the related preclinical drug therapy of ARDS in recent years from two aspects: the uncontrolled inflammatory response and the destruction of alveolar epithelial and pulmonary vascular endothelial barrier, in order to provide reference for the later treatment of ARDS.
